Abstract: Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the liquid compositions of the present invention are also detailed herein.

Abstract: The present invention relates to a bowel cleansing composition comprising polyethylene glycol and ascorbate ingredients, the bowel cleansing composition of the present invention being easier to take, while having an excellent bowel cleansing effect, thereby being usable as an effective bowel cleansing agent.

Abstract: Disclosed is a method for controlling a biofilm, for removing a formed biofilm and/or for controlling a growth of microorganisms, preferably bacteria, in an aqueous environment of an industrial manufacturing process including cellulosic fibre material. In the method, a composition including a compound selected from a group consisting of 3-[(4-methylphenyl)sulphonyl]-2-propenenitrile and 4-amino-N-2-thiazolyl-benzenesulphonamide is administered to the aqueous environment of the process.

Abstract: Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure to baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.

Abstract: A stable liquid composition contained in a bottle wherein the composition comprises from about 0.001% to about 0.5% of phenylephrine hydrochloride, by weight of the stable liquid composition. The composition comprises less than about 0.1% of total aldehydes, by weight of the stable liquid composition, and has a pH from about 2 to about 6.5. The bottle comprises a material selected from polyethylene terephthalate (PET), glycol-modified polyethylene terephthalate (PETG), oriented polypropylene (OPP), polyvinylchloride (PVC), polyvinylidene chloride (PVDC), nylon, polyethylene terephthalate polyester (PETP), or combinations thereof.

Abstract: A compound having the formula (I) R1-COOH. R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof. The backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the ? carbon of R1, or of only single methyl groups at both the ? and ?-1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1.

Abstract: Methods to prevent ketosis or minimize the effects of ketosis in ruminant animals are provided. This methods include feeding to the animal biotin in combination with a mixture of at least two essential oil compounds selected from the group consisting of thymol, eugenol, meta-cresol, vaniline and guajacol. The methods usefully prevent and/or inhibit ketosis of calving ruminant animals and the subsequent need for veterinary treatment. In a preferred embodiment of a feeding concept for dairy cattle, especially calving dairy cattle, biotin is used in an amount sufficient to provide a daily dosage of 10 mg to 20 mg per head to which it is to be administered. It is at present contemplated that the essential oils are administered in amounts (total dosage ranges of essential oils) of 1 to 1.5 g per head per day.

Abstract: Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Abstract: Provided herein is a group of sphingosine analogs, useful in the treatment of bacterial infections in mucosal surfaces such as lungs, caused by pathogenic bacteria which are typical to disorders and diseases such as CF and COPD.

Abstract: The invention provides methods of improving sleep in a patient having a variant of the cryptochrome circadian clock 1 (CRY 1) genotype associated with a circadian rhythm sleep disorder (CRSD) Delayed Sleep Wake Phase Disorder (DSWPD).

Abstract: Methods and compositions for treating or preventing muscle wasting resulting from an underlying disease or disorder, such as cancer cachexia. A therapeutically effective amount of a ketogenic supplement—such as R,S 1,3 butanediol diacetoacetate, R,S 1,3-butanediol acetoacetate diester, derivatives thereof, or combinations thereof—is administered to a patient or subject in need. The ketogenic supplement may further include a medium chain triglyceride in combination with the ketone ester.

Abstract: This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with a Bruton's tyrosine kinase (BTK) inhibitor.

Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1, 3,4, 6,7,11 b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.

Abstract: Highly concentrated solutions are disclosed along with methods of inhibiting and/or ameliorating functional neurological disorders of the brain. The method may include administering directly to a brain of a subject a medicament multiple times over a time period of at least two days. The medicament may include a half-life of less than 2 hour in the cerebrospinal fluid. The method may include inhibiting and/or ameliorating a functional neurological disorder of the brain using the medicant.

Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.

Abstract: Methods for repelling Drosophila species (e.g., D. suzukii, D. melanogaster) involving treating an object or area with a composition containing a Drosophila species (e.g., D. suzukii, D. melanogaster) repelling effective amount of 2-pentylfuran and optionally a carrier.

Abstract: The present invention relates to compound of formula (I): wherein R is O—R3 or R1 and R2 are identical or different and are each independently H, (C1-C6)alkyl, —CO—(C1-C21)alkyl or —CO—(C11-C21)alkenyl group, provided that at least one of R1 or R2 is H or (C1-C6)alkyl, R3 is a —CO—(C11-C21)alkyl or —CO—(C11-C21)alkenyl group, or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof, for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

Abstract: A compound having the formula (I) R1-COOH. R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof. The backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the ? carbon of R1, or of only single methyl groups at both the ? and ?-1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1.

Abstract: An aspect of the present disclosure is directed to an oral liquid composition comprising valsartan with enhanced solubility and stability. Other aspects are directed to methods of using the oral liquid compositions for the treatment of hypertension, treatment of heart failure and reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction.

Abstract: Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.